AMLX has had major setbacks in its lifecycle, including the voluntary withdrawal of an approved drug. Click here to find out ...

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) is expected to be releasing its earnings data before the market opens ...

A live webcast of both presentations can be accessed under "Events and Presentations" in the Investor section of the Company’s website, ...

Amylyx Pharmaceuticals (NASDAQ:AMLX) has priced a public offering of ~17.14M shares of its common stock at $3.50 a share. In addition, Amylyx has granted the underwriter a 30-day option to ...

Amylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next day ...

NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten ...

Amylyx Pharmaceuticals said the Food and Drug Administration had lifted its clinical hold on a trial of the company's treatment for patients with ALS. The Cambridge, Mass., company is now working ...

Amylyx Pharmaceuticals, Inc. (AMLX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of shares ...